Summary
Improved treatment approaches for seasonal allergic rhinitis are based on the increasing knowledge about allergic inflammation and on the improved efficacy of newer drugs. The current management concept includes an individualised composition of the different approaches including allergen avoidance, topical treatment and the use of systemic drugs and specific immunotherapy.
Allergen avoidance, supported by pollen information, leads to a remarkable reduction of daily challenge situations. There is an increasing trend towards topical use of corticosteroids (e.g. budesonide and fluticasone) and mast cell stabilisers [e.g. sodium cromoglycate (cromolyn sodium), nedocromil and isospaglumic acid (N-acetylaspartylglutamic acid)] because of the potency of these drugs to impair the destructive activity of allergic inflammation.
Potent histamine H1-receptor antagonists (e.g. azelastine and levocabastine) are approved for local treatment and lead to prompt relief of troublesome symptoms. A new generation of orally active antihistamines (e.g. astemizole, cetirizine, loratadine and terfenadine) have tended to be called ‘antiallergics’ because of activity other than H1-blockade. Furthermore, these newer compounds are less likely to cause sedation.
Immunotherapy is still an integrated component in the treatment strategy. Standardised allergen extracts of high quality raise the treatment efficacy and safety.
Overall, forming an individual combination of treatment approaches gives the best result.
Similar content being viewed by others
References
Andri L, Senna GE, Betteli C, Andri G, Scaricabarozzi I, et al. Use of nimesulide in allergic rhinitis: preliminary results. Abstract. Schweizerische Medizinische Wochenschrift 121 (Suppl. 40/II): P2 047, 19, 1991
Billah MM, Gilchrest HG, Eckel SP, Granzow CA, Lawton PJ, et al. Differential plasma duration of antiplatelet-activating factors and antihistamine activities of oral Sch 37370 in humans. Clinical Pharmacology and Therapeutics 52: 151–159, 1992
Billah MM, Chapman RW, Watnick AS, Egan RW, Siegel MI, et al. Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. Agents and Actions 34 (Suppl.): 313–321, 1991
Borum P, Larsen FS. Seasonal allergic rhinitis treated with a beta-2-adrenostimulant. Allergy 42: 141–145, 1987
Bousquet J, Hejjaoui A, Michel FB. Specific immunotherapy in asthma. Journal of Allergy and Clinical Immunology 86: 292–305, 1990
Breiteneder H, Pettenburger K, Bito A, Kraft D, Rumpold H, et al. The gene coding for the major birch allergen, Bet v I, is highly homologous to a pea disease resistance response gene. EMBO Journal 8: 1935–1938, 1989
Brogden RN, Me Tavish D. Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs 41: 927–940, 1991
Brunet C, Bedard PM, Lavoie A, Jobin M, Herbert J. Allergic rhinitis to ragweed pollen. I. Reassessment of the effects of immunotherapy on cellular and humoral responses. Journal of Allergy and Clinical Immunology 89: 76–86, 1992
Bryson HM, Faulds D. Intranasal fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis. Drugs 43: 760–775, 1992
Busse WW, Orr TSC, Pauwels R (Eds). International symposium on nedocromil sodium. Drugs 37; (Suppl. 1) (1–137): 1989
Dechant KL, Goa KL. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs 41: 202–224, 1991
De Clerck F, Van Glabbeek G, Somers, Y. Astemizole inhibits PAF-induced bronchoconstriction in vivo in guinea-pigs by antagonizing effects of locally released histamine. Abstract. Allergy and Clinical Immunology News (Suppl. 1): 292, 1991
Ghaem A. A preliminary evaluation of the effect of Nacetyl-as-partyl-glutamate on pollen nasal challenge as measured by rhi-nomanometry and symptomatology. Allergy 42: 626–630, 1987
Gonzalez JP, Brogden RN. Nedocromil sodium. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstruction airways disease. Drugs 43: 560–577, 1987
Greenbaum J, Leznoff A, Schulz J, Mazza J, Tobe A, et al. Comparative tolerability of two formulations of Rhinalar (fluni-solide) nasal spray in patients with seasonal allergic rhinitis. Annals of Allergy 61: 305–310, 1988
Haidvogl M. Alternative treatment possibilities of atopic diseases. Pädiatric Pathology 25: 389–396, 1990
Holgate ST, Goa KL, Horak F, Knight A, Möller C (Eds). Astemizole — a review of clinical experience, pp. 1–82, Adis Press, Manchester, 1988
Horak F. Budesonid und Beclomethasondipropionat in der Behandlung der allergischen Rhinitis — Eine vergleichende Untersuchung, HNO Nachrichten, München 73: 1852–1856, 1987
Horak F. Results of the Vienna provocation study: onset of action of intranasal and oral azelastine in pollen-induced allergic rhinitis. Abstract. Allergy 47 (Suppl.): 6–7, 1992
Horak F, Jäger S, Andresen I. Dose finding of dimethindene maleat in pollinosis — as a new galenic formula. Abstract. Schweizerische Medizinische Wochenschrift 121 (Suppl. 40/II): P2 023, 13, 1991
Horak F, Jäger S, Berger U. A new approach to estimate efficacy of local nasal immunotherapy. Notiziario Allergologico 9: 189–198, 1990
Horak F, Jäger S, Berger U. Onset and duration of the effects of three antihistamines in current use — astemizole, loratadine and terfenadine forte — studied during prolonged, controlled allergen challenges in volunteers. Journal of International Medical Research 20: 422–434, 1992a
Horak F, Matthes H. The protective action of fluocortin butylester (FCB) in the nasal antigen provocation test: a controlled doubleblind, crossover study. Annals of Allergy 48: 305–308, 1982
Horak F, Toth J, Jäger J, Berger U. Effect of H1-receptor antagonists on nasal obstruction in atopic patients. Allergy 47: in press, 1992b
Horak F, Wheeler AW. Oral hyposensitization with enteric-coated allergens as extension therapy following a basic subcutaneous course of injections. International Archives of Allergy and Applied Immunology 84: 74–78, 1987
Hömberg K, Pipkorn U, Bake B, Blychert LO. Effects of topical treatment with H1 and H2 antagonists on clinical symptoms and nasal vascular reaction in patients with allergic rhinitis. Allergy 44: 281–287, 1989
Jäger S. EANS — European Aeroallergen Network Server. Aero-biologia 4: 16–19, 1988
Jalkut SI, Gulling EV. Vilosen — is a new antiallergic preparation. Abstract. Allergy 47 (Suppl. 12): 173, 1992
Kaulbach HC, Igarashi Y, Mullol J, White MV, Kaliner MA. Effects of nedocromil sodium on allergen-induced rhinitis in humans. Journal of Allergy and Clinical Immunology 89: 599–610, 1992
Keating MU, Kagey-Sobotka A, Hamilton RG, Yunginger JW. Clinical and immunological follow-up of patients who stop venom immunotherapy. Journal of Allergy and Clinical Immunology 88: 339–348, 1991
Knight A, Drouin M, Yang W, Alexander M, Del Carpio J, et al. Clinical evaluation of efficacy and safety of noberastine, a new H1 antagonist, in seasonal allergic rhinitis: a placebo-controlled, dose-response study. Journal of Allergy and Clinical Immunology 88: 926–934, 1991
Leggieri E, Tedeschi A, Lorini M, Bianco A, Miadonna A. Study of the effects of paf-acether on human nasal airways. Allergy 46: 466–471, 1991
Liu WL, Pearce FL, Theraulaz-Lacroix M, Towart R. Mast-cell stabilising effects of dimethindene maleate (fenistil) and its optical isomers. Abstract. Schweizerische Medizinische Wochenschrift 121 (Suppl. 40/II): P2 009, 10, 1991
Machiels JJ, Somville MA, Jacquemin MG, Saint-Remy JM. Allergen-antibody complexes can efficiently prevent seasonal rhinitis and asthma in grass pollen hypersensitive patients. Allergen-antibody complex immunotherapy. Allergy 46: 335–348, 1991
Majchel AM, Proud D, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. Ketotifen reduces sneezing but not histamine release following nasal challenge with antigen. Clinical and Experimental Allergy 20: 701–705, 1990
Mailing HJ, Weeke B. EAACI immunotherapy position paper, 1992 revised version. Allergy 47 (Suppl.): in press, 1992
McTavish D, Goa KL, Ferrill M. Terfenadine: an update review of its pharmacological properties and therapeutic efficacy. Drugs 39: 552–551, 1990
McTavish D, Sorkin EM. Azelastine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 38: 778–800, 1989
Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment?. Allergy 43: 523–529, 1988
Nathan RA, Bronsky EA, Fireman P, Grossman J, La Force CF, et al. Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. Annals of Allergy 67: 332–338, 1991
Ophir D, Elad Y, Dolev Z, Geller-Bernstein C. Effects of inhaled humidified warm air on nasal patency and nasal symptoms in allergic rhinitis. Annals of Allergy 60: 239–242, 1988
Pipkorn U, Granerus G, Proud D, Kagey-Sobotka A, Norman PS, et al. The effect of a histamine synthesis inhibitor on the immediate nasal allergic reaction. Allergy 42: 496–501, 1987
Rosenzweig P, Thebault JJ, Caplain H, Dubruc C, Bianchetti G, et al. Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine. Annals of Allergy 69: 135–139, 1992
Scheiner O, Bohle B, Breitenbach M, Breiteneder H, Duchene M, et al. Recombinant allergens: production and possible clinical implications. In Godard et al. (Eds) Advances in allergology and clinical immunology, pp. 115–126, Parthenon Publishing Group, Lancs. (UK) and New Jersey (USA), 1992
Taudorf E, Laursen LC, Lanner A, Bjorksten B, Dreborg S, et al. Oral immunotherapy in birch pollen hay fever. Journal of Allergy and Clinical Immunology 80: 153–161, 1987
Tinkelman D, Falliers C, Gross G, Segal A, Southern L, et al. Multicenter evaluation of triamcinolone acetonide nasal aerosol in the treatment of adult patients with seasonal allergic rhinitis. Annals of Allergy 64: 234–240, 1990
Vanzieleghem MA, Juniper EF. A comparison of budesonide and beclomethasone dipropionate nasal aerosols in ragweedin-duced rhinitis. Journal of Allergy and Clinical Immunology 79: 887–892, 1987
Walsh GM, Moqbel R, Hartneil A, Kay AB. Effects of cetirizine on human eosinophil and neutrophil activation in vitro. International Archives of Allergy and Applied Immunology 95: 158–162, 1991
Yakatan G, Dennis S, Prenner B, Rangus K, Wold R. Pentigetide: efficacy in patients with allergic rhinitis. Abstract. Allergy Proceedings 9: 372, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Horak, F. Seasonal Allergic Rhinitis. Drugs 45, 518–527 (1993). https://doi.org/10.2165/00003495-199345040-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199345040-00004